AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32931398
Drug: Ibrutinib at
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib at 420 mg/d
Trial: 32931710
Drug: Risk medication
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk medication usage
Trial: 32931710
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) usage
Trial: 32933874
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) in combination with a new-generation drug-eluting stent (DES)
Trial: 32934619
Drug: 3% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% prilocaine with 3% felypressin (0.03 I.U. per ml)
Trial: 32934722
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy in patients with high cyclin D1 expression (cN2 stage)
Trial: 32936949
Drug: Antimicrobial mouthwashes
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial mouthwashes and nasal sprays (e.g., povidone iodine, nitric oxide, GLS-1200 oral spray)
Trial: 32936949
Drug: Antimicrobial mouthwashes
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial mouthwashes and nasal sprays
Trial: 32936949
Drug: Antimicrobial mouthwashes
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial mouthwashes and nasal sprays (if administered to patients)
Trial: 32938595
Drug: Prescribing rates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribing rates across medication classes used in AD (emollients, topical corticosteroids by potency, topical calcineurin inhibitors, topical antimicrobials, antihistamines, oral corticosteroids, and systemic immunomodulatory therapies).
Trial: 32938595
Drug: Treatment escalation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment escalation in people first diagnosed with AD during the study period, analyzed using time-to-event analysis.
Trial: 32939459
Drug: Ledipasvir 90
RxNorm normalized name: ledipasvir 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir 90 mg plus sofosbuvir 400 mg (daily for 12 weeks)
Trial: 32939607
Drug: Crenigacestat 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat 25 mg, administered orally 3 times per week over a 28-day cycle
Trial: 32939607
Drug: Crenigacestat 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenigacestat 50 mg, administered orally 3 times per week over a 28-day cycle
Trial: 32940955
Drug: N8-GP (turoctocog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for 50 exposure days (~26 weeks)
Trial: 32940955
Drug: N8-GP (turoctocog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N8-GP (turoctocog alfa pegol) 60 IU/kg, twice-weekly for a median time of ~4.9 years
Trial: 32941876
Drug: Plasma cadmium
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma cadmium levels (58 ng/L median)
Trial: 32943098
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg/month for 7 infusions)
Trial: 32943160
Drug: Recommended dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dosing of DOACs
Trial: 32943160
Drug: Nonrecommended dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonrecommended dosing of DOACs (combined underdosing and overdosing)
Trial: 32943286
Drug: Donor-specific antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor-specific antibodies
Trial: 32943410
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (patients not receiving antifibrotic therapy)
Trial: 32945202
Drug: Intravenous dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dipyridamole (DP)
Trial: 32945596
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg/day for ≥ 2 weeks
Trial: 32945596
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of ethinylestradiol (EE) 30 μg and levonorgestrel (LN) 150 μg
Trial: 32945596
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of bupropion (75 mg) and midazolam (2 mg)
Trial: 32946725
Drug: Antiretroviral therapy-naive
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy-naive patients
Trial: 32947291
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin with lactated Ringer's solution
Trial: 32949123
Drug: Cognitive Functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Functional Therapy (CFT) for 14 weeks
Trial: 32949150
Drug: Regorafenib treatment
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib treatment
Trial: 32949176
Drug: Anlotinib 12
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg p.o. once every day (days 1-14, with a 21-day cycle)
Trial: 32949176
Drug: Oral temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral temozolomide chemotherapy 100 mg/m²
Trial: 32949828
Drug: Re-biopsy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-biopsy after first line treatment
Trial: 32950058
Drug: Eculizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab treatment during kidney transplantation
Trial: 32950419
Drug: Prasugrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel monotherapy for 3 months
Trial: 32951151
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma administered early in the disease course (severe illness group)
Trial: 32951684
Drug: Personalized dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized dose of fish oil (mean target dose 6.63 g/day to 4.06 g/day)
Trial: 32951684
Drug: Dynamic modeling
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic modeling of fish oil dosing
Trial: 32951684
Drug: Bayesian design
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian design for dosing algorithm
Trial: 32954238
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application UnityPhilly for naloxone administration
Trial: 32954622
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients (combined treatment)
Trial: 32958482
Drug: Post-treatment IgM
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment IgM concentrations
Trial: 32958628
Drug: Hybrid Closed-Loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid Closed-Loop Insulin Therapy
Trial: 32958709
Drug: 140-mg loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140-mg loading dose of caspofungin (CAS)
Trial: 32959922
Drug: H. perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. perforatum extract (after 2 weeks treatment)
Trial: 32959922
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline measurements before H. perforatum treatment)
Trial: 32963347
Drug: buparlisib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buparlisib monotherapy
Trial: 32963347
Drug: buparlisib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buparlisib and cetuximab combination
Trial: 32964020
Drug: Trandolapril/Verapamil fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril/Verapamil fixed-dose combination
Trial: 35445317
Drug: Passeo-18 Lux
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Passeo-18 Lux drug-coated balloon (DCB)
Trial: 32965548
Drug: Iberdomide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.6 mg) alone
Trial: 32965548
Drug: Iberdomide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.6 mg) with itraconazole (200 mg twice daily on day 1 and 200 mg once daily on days 2 through 9)
Trial: 32965548
Drug: Iberdomide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.6 mg) with rifampin (600 mg QD days 1 through 13)
Trial: 32965659
Drug: Ivacaftor 150
RxNorm normalized name: ivacaftor 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivacaftor 150 mg orally every 12 hours for 104 weeks
Trial: 32967009
Drug: CART2 (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CART2 (second infusion of CD19 CAR T cells)
Trial: 32967807
Drug: Daratumumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab monotherapy (16 mg/kg, intravenously weekly for 8 weeks, biweekly for 16 weeks, and every 4 weeks thereafter)
Trial: 32968710
Drug: Intravenous Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Golimumab (GLM-IV)
Trial: 32969724
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) 5 mg/kg/d
Trial: 32971036
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin)
Trial: 32972204
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose during CTO-PCI
Trial: 32972320
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of antiphospholipid antibodies (mainly lupus anticoagulant)
Trial: 32974150
Drug: Radical Intensity-Modulated
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical Intensity-Modulated Radiation Therapy
Trial: 32974208
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) and pelvic lymph node coverage.
Trial: 32975711
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination therapy with two glucose-lowering drugs
Trial: 32975711
Drug: Stepwise approach
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise approach starting with metformin
Trial: 32975869
Drug: Isatuximab 20
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab 20 mg/kg QW/Q2W
Trial: 32976514
Drug: Semi-annual MDA
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Trial: 32976514
Drug: Annual MDA
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Trial: 32977309
Drug: 124I-8H9 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 124I-8H9 monoclonal antibody (124I-omburtamab) administered by CED
Trial: 32977309
Drug: Second infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second infusion of 124I-8H9 monoclonal antibody (124I-omburtamab)
Trial: 32977309
Drug: First and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First and second infusions of 124I-8H9 monoclonal antibody (124I-omburtamab)
Trial: 32977351
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or conventional treatment (including blood transfusion and hydroxyurea)
Trial: 32978101
Drug: Tyrosine and
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine and serine/threonine kinase inhibitors (TKIs)
Trial: 32978101
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of at least three concomitant medications
Trial: 32979106
Drug: Docetaxel (D)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (D) 75 mg/m²
Trial: 32979106
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of docetaxel and pegylated liposomal doxorubicin
Trial: 32979560
Drug: Adjunctive brexpiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brexpiprazole 2-3 mg/day for 8 weeks
Trial: 32979984
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and nivolumab
Trial: 32979984
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with intravenous paclitaxel and nivolumab
Trial: 32980364
Drug: Control (recent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (recent ACE inhibitor/ARB initiation/dose change)
Trial: 32980834
Drug: ω-3 fatty
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 fatty acids and low-dose aspirin as adjuncts to periodontal debridement
Trial: 32982210
Drug: Enjoying Breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enjoying Breathing Program intervention including online and face-to-face courses for health care providers, standard therapy, self-management education, rehabilitation exercises, and follow-up every 3 months.
Trial: 32982387
Drug: Post-operative morphine
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative morphine
Trial: 32982933
Drug: Purified Anthocyanins,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Anthocyanins, dosage and duration not available
Trial: 32982944
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose of Atorvastatin
Trial: 32982950
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Virtual Reality and Transcranial Direct Current Stimulation
Trial: 32983991
Drug: S-1-based chemoradiotherapy
RxNorm normalized name: menthol 1 MG [Luden's]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1-based chemoradiotherapy followed by consolidation chemotherapy with S-1
Trial: 32984371
Drug: Non-invasive drug
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive drug monitoring of β-Lactam antibiotics using sweat analysis
Trial: 32987824
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance tests (OGTT) with doses of 25 g, 75 g, and 125 g
Trial: 32987824
Drug: Isoglycaemic intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycaemic intravenous (i.v.) glucose infusions (IIGI)
Trial: 32988829
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (10 mg/kg of body weight/6 h)
Trial: 32988829
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral acyclovir
Trial: 32988948
Drug: Oral steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids, intratympanic steroid injections, or a combination of both (exact dosages and durations not specified)
Trial: 32989226
Drug: ODM-207 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM-207 (2 mg/kg)
Trial: 32989552
Drug: JTX-4014 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTX-4014 (500 mg every 3 weeks or 1000 mg every 6 weeks)
Trial: 32989776
Drug: First-line tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line tyrosine kinase inhibitors (TKIs)
Trial: 32989856
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma treatment
Trial: 32990181
Drug: Carcinogenic HPVs
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carcinogenic HPVs in nonavalent vaccine (HPV16,18,31,33,45,52,58)
Trial: 32990324
Drug: Mepolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (300 mg; three separate injections every four weeks for 52 weeks)
Trial: 38393328
Drug: Mepolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (300 mg)
Trial: 32990324
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice a week) or Belimumab (10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy
Trial: 32990324
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice a week)
Trial: 32990629
Drug: Video directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video directly observed therapy (VDOT) with smartphone app, weekly internet subscription, translated text message reminders, and incentives for adherence
Trial: 32990629
Drug: Usual-care directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-care directly observed therapy (DOT)
Trial: 32990938
Drug: Extended-release dinalbuphine
RxNorm normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release dinalbuphine sebacate (ERDS)
Trial: 32990945
Drug: Pine bark
RxNorm normalized name: pine bark extract
DrugBank: Maritime pine extract (DB15786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pine bark extract supplements
Trial: 32991329
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to multiple SARS-CoV-2 antigens
Trial: 32991329
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to HCoV-OC43 and HCoV-HKU1 spike S2
Trial: 32992048
Drug: Angiotensin-converting-enzyme inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting-enzyme inhibitors (ACEI)
Trial: 32992048
Drug: Angiotensin-receptor blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-receptor blockers (ARB)
Trial: 32992341
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy (3 cycles) followed by AVD chemotherapy (4 to 6 cycles)
Trial: 32992341
Drug: AVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVD chemotherapy (after pembrolizumab)
Trial: 32992341
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy followed by AVD
Trial: 32993275
Drug: BPH screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPH screening tool (score ≥3) and serum PSA ≥2 ng/mL
Trial: 32993275
Drug: IPSS ≥8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPSS ≥8 and serum PSA ≥2 ng/mL
Trial: 32993521
Drug: CRP cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP cut-off of 3 mg/l
Trial: 32993559
Drug: PZQ treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ treatment immediately after diagnosis
Trial: 32993559
Drug: PZQ treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ treatment after delivery
Trial: 32993772
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Alzheimer's biomarkers (t-Tau, P-Tau, Aβ42, Aβ40)
Trial: 32993794
Drug: BEZ235 (300-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 (300-400 mg BID)